Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center

被引：0
|
作者：
Michael D. Nailor
Kellie J. Goodlet
Omar Gonzalez
J. Tyler Haller
机构：
[1] St. Joseph’s Hospital and Medical Center,Department of Pharmacy Services
[2] Midwestern University College of Pharmacy,Department of Pharmacy Practice
[3] Arizona Pulmonary Specialists,Infectious Disease Division
[4] Barrow Neurological Institute,undefined
[5] St. Joseph Hospital and Medical Center,undefined
来源：
CNS Drugs | 2024年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 229
页数：4
相关论文
共 50 条
  • [21] Sharp ill-effects after the administration of liposomal amphotericin B
    Portillo-Cano, Maria del Mar
    Lobo-Acosta, Maria Angeles
    Rios-Villegas, Maria Jose
    Alanis-Lopez, Joaquin
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (05): : 352 - 352
  • [22] ACUTE TOXIC DELIRIUM - NEUROTOXICITY OF INTRATHECAL ADMINISTRATION OF AMPHOTERICIN-B
    WINN, RE
    BOWER, JH
    RICHARDS, JF
    ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (06) : 706 - 707
  • [23] Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate
    Bekersky, I
    Fielding, RM
    Dressler, DE
    Lee, JW
    Buell, DN
    Walsh, TJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 834 - 840
  • [24] Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis
    Castagnola, E
    Davidson, RN
    Fiore, P
    Tasso, L
    Rossi, G
    Mangraviti, S
    DiMartino, L
    Scotti, S
    Cascio, A
    Pempinello, R
    Gradoni, L
    Giacchino, R
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (03) : 317 - 318
  • [25] COMPARISON OF A LIPOSOMAL AMPHOTERICIN-B FORMULATION (AMBISOME) AND DEOXYCHOLATE AMPHOTERICIN-B (FUNGIZONE) FOR THE TREATMENT OF MURINE PARACOCCIDIOIDOMYCOSIS
    CLEMONS, KV
    STEVENS, DA
    JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, 1993, 31 (05): : 387 - 394
  • [26] Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats
    Boswell, GW
    Bekersky, I
    Buell, D
    Hiles, R
    Walsh, TJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 263 - 268
  • [27] Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity
    Sabra, R
    Zeinoun, N
    Sharaf, LH
    Ghali, R
    Beshara, G
    Serhal, H
    PHARMACOLOGY & TOXICOLOGY, 2001, 88 (04): : 168 - 175
  • [28] PHARMACOKINETICS AND SAFETY OF A UNILAMELLAR LIPOSOMAL FORMULATION OF AMPHOTERICIN-B (AMBISOME) IN RABBITS
    LEE, JW
    AMANTEA, MA
    FRANCIS, PA
    NAVARRO, EE
    BACHER, J
    PIZZO, PA
    WALSH, TJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) : 713 - 718
  • [29] Safety and tolerability of intrathecal liposomal amphotericin B (AmBisome) in HIV infected patients with cryptococcal meningitis
    Alvarez-Uria, G.
    Battula, J.
    Pujari, H.
    Vengakal, S.
    Talari, L.
    Midde, M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S82 - S82
  • [30] Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections
    Isnard, F.
    Tilleul, P.
    Laporte, J.-P.
    Chevallier, P.
    Pigneux, A.
    Lafuma, A.
    Monchecourt, F.
    Mahi, L.
    Deray, G.
    MEDECINE ET MALADIES INFECTIEUSES, 2008, 38 (04): : 208 - 214
12345